Tough FDA panel review in sight for B+L?
This article was originally published in Clinica
Executive Summary
Bausch + Lomb’s Trulign Toric intraocular lens could face a grilling at an FDA advisory panel meeting today, if the agency’s briefing documents are anything to go by. If given the thumbs up by the panel, the device could become the first toric accommodating IOL to be approved by the FDA – it is intended for lens replacement in cataract patients to restore both accommodation (the ability to focus on near objects) and correction of corneal astigmatism.